A PLACEBO-CONTROLLED, PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF RECOMBINANT ENVELOPE PROTEINS OF HIV-1 GP160 AND GP120 IN CHILDREN >= 1 MONTH OLD WITH ASYMPTOMATIC HIV INFECTION: